Mutual of America Capital Management LLC Decreases Stake in Eli Lilly and Company $LLY

Mutual of America Capital Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 1.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 92,200 shares of the company’s stock after selling 1,749 shares during the period. Eli Lilly and Company accounts for 0.8% of Mutual of America Capital Management LLC’s investment portfolio, making the stock its 14th largest holding. Mutual of America Capital Management LLC’s holdings in Eli Lilly and Company were worth $71,873,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Signature Estate & Investment Advisors LLC lifted its position in shares of Eli Lilly and Company by 199.5% in the second quarter. Signature Estate & Investment Advisors LLC now owns 55,433 shares of the company’s stock worth $43,212,000 after buying an additional 36,923 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV raised its position in Eli Lilly and Company by 5.0% during the second quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 2,378 shares of the company’s stock valued at $1,854,000 after purchasing an additional 114 shares during the period. Novare Capital Management LLC raised its position in Eli Lilly and Company by 114.0% during the second quarter. Novare Capital Management LLC now owns 4,000 shares of the company’s stock valued at $3,118,000 after purchasing an additional 2,131 shares during the period. Quotient Wealth Partners LLC raised its position in Eli Lilly and Company by 11.2% during the second quarter. Quotient Wealth Partners LLC now owns 3,726 shares of the company’s stock valued at $2,905,000 after purchasing an additional 374 shares during the period. Finally, MPS Loria Financial Planners LLC raised its position in Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, UBS Group cut their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $939.12.

Eli Lilly and Company Trading Down 1.9%

LLY opened at $803.53 on Friday. The stock has a market cap of $760.51 billion, a price-to-earnings ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47. The stock’s 50 day moving average price is $753.09 and its 200-day moving average price is $765.86. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.